Evidence map›Paper›PMID 36458435›Full record

ArticleCancer discovery2022

A Deep Dive into the Circulating ctDNA Cosmos to Vanquish Neuroblastoma.

Hedwig E Deubzer, Kathy Astrahantseff, Marco Lodrini

Open access · bronzeAbstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Hedwig E DeubzerDepartment of Pediatric Oncology and Hematology, Charité-Universitäts-medizin Berlin, Berlin, Germany.ORCID 0000-0002-6115-4893
Kathy AstrahantseffDepartment of Pediatric Oncology and Hematology, Charité-Universitäts-medizin Berlin, Berlin, Germany.ORCID 0000-0002-7872-1997
Marco LodriniDepartment of Pediatric Oncology and Hematology, Charité-Universitäts-medizin Berlin, Berlin, Germany.ORCID 0000-0003-4434-529X
Charité - Universitätsmedizin Berlin · DEGerman Cancer Research Center · DEMax Delbrück Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

summarySingle biopsies fail to reflect intratumor heterogeneity and tumor evolution. In this issue of Cancer Discovery, Bosse and colleagues show an important role for circulating cell-free tumor DNA sequencing to detect the genomic evolution of neuroblastoma under ALK inhibitor therapy and identify novel (sub)clonal pathogenic variants involved in disease progression under conventional therapy. See related article by Bosse et al., p. 2800 (5).

Indexed as

Cell-Free Nucleic AcidsCirculating Tumor DNANeuroblastomaAcetaminophenAspirinGenomicsHumansAcetaminophenAspirinCell-Free Nucleic AcidsCirculating Tumor DNA

Identifiers

PMID36458435
OpenAlexW4310703801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.